Cost-effectiveness of managing HIV infection

Abstract

The worldwide spread of HIV infection continues, particularly in economically vulnerable, developing and emerging countries. There is a lack of resources to supply effective prevention measures and apply highly active antiretroviral therapies. In the regions concerned, economical effects of morbidity- and mortality-associated productivity losses in those of a working age remain serious. Thus, the United Nations Program on HIV/AIDS and the World Health Organization have predicted a dramatic decrease of South Africa’s and other African states’ domestic product in the coming years. Therefore, with the world economical consequences from the HIV pandemic, a large political challenge in the next 10 years will arise.

• cost-effectiveness
• direct costs
• indirect costs